{"entity":{"id":"frank-mccormick","kind":"person","name":"Frank McCormick","aka":[],"tldr":"RAS biologist who founded Onyx Pharmaceuticals and led the NCI's national effort to drug RAS.","summary":"Frank McCormick is Professor at the UCSF Helen Diller Family Comprehensive Cancer Center and former Scientific Lead of the RAS Initiative at the National Cancer Institute (NIH). A molecular biologist who has worked on RAS signalling for four decades, he founded Onyx Pharmaceuticals, the company behind the origins of sorafenib and carfilzomib, and served as scientific lead of the NCI RAS Initiative at Frederick National Laboratory. His papers include a Clinical Cancer Research review of KRAS as a therapeutic target and a Cancer Cell commentary on covalent KRAS inhibitors entering the clinic. His work on KRAS and RAS inhibitors bears on pancreatic ductal adenocarcinoma, colorectal cancer and non-small-cell lung cancer.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Frank%20McCormick"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=McCormick%20F%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Frank%20McCormick"}],"tags":[],"related":[],"cancers":["pancreatic","colorectal","nsclc"],"sections":[],"technologies":["kras-inhibitors"],"targets":["kras"],"drugs":[],"companies":[],"institutions":["ucsf","nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-cell"],"dependsOn":[],"notes":[],"role":"Professor, UCSF Helen Diller Family Comprehensive Cancer Center; former Scientific Lead, NCI RAS Initiative","institutionId":"ucsf","specialisms":["RAS biology","Signal transduction","Drug discovery"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Frank%20McCormick"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=McCormick%20F%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Frank%20McCormick"}],"papers":[{"title":"KRAS as a Therapeutic Target","journal":"Clinical Cancer Research","year":2015,"url":"https://doi.org/10.1158/1078-0432.CCR-14-2662","doi":"10.1158/1078-0432.CCR-14-2662"},{"title":"Sticking it to KRAS: Covalent Inhibitors Enter the Clinic","journal":"Cancer Cell","year":2020,"url":"https://doi.org/10.1016/j.ccell.2019.12.009","doi":"10.1016/j.ccell.2019.12.009"}],"orcid":"0000-0002-6619-7120"},"route":"/people/frank-mccormick/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"institution":[{"id":"frederick-national-lab","kind":"institution","name":"Frederick National Laboratory for Cancer Research","route":"/institutions/frederick-national-lab/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"},{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}],"journal":[{"id":"cancer-cell","kind":"journal","name":"Cancer Cell","route":"/journals/cancer-cell/"}],"paper":[{"id":"paper-bischoff-onyx-015-science-1996","kind":"paper","name":"Bischoff 1996: the adenovirus that was said to replicate only where p53 was lost","route":"/key-papers/paper-bischoff-onyx-015-science-1996/"},{"id":"paper-almoguera-kras-codon-12-pancreatic-cell-1988","kind":"paper","name":"Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes","route":"/key-papers/paper-almoguera-kras-codon-12-pancreatic-cell-1988/"}]}}